{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:50:07Z","timestamp":1782604207624,"version":"3.54.5"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,1]]},"DOI":"10.2169\/internalmedicine.1760-23","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T22:11:06Z","timestamp":1689113466000},"page":"3203-3207","source":"Crossref","is-referenced-by-count":3,"title":["Encapsulating Peritoneal Sclerosis in a Patient Receiving Peritoneal Dialysis and Glucocorticoid Therapy"],"prefix":"10.2169","volume":"62","author":[{"given":"Kensei","family":"Taguchi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Mitsuishi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuya","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fukami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nakayama M, Miyazaki M, Honda K, et al. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int 34: 766-774, 2014.","DOI":"10.3747\/pdi.2013.00074"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 44: 729-737, 2004.","DOI":"10.1016\/S0272-6386(04)00953-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tseng CC, Chen JB, Wang IK, et al. Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS. PLoS One 13: e0190079, 2018.","DOI":"10.1371\/journal.pone.0190079"},{"key":"4","unstructured":"4. Mihalache O, Bug\u0103 C, Doran H, Catrina E, Bobirc\u0103 F, P\u0103tra\u015fcu T. Encapsulating Peritoneal Sclerosis - a rare and serious complication of peritoneal dialysis: case series. J Med Life 7: 8-12, 2014."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mizumasa T, Honda K, Aoki S, et al. Proposal of peritoneal biopsy procedures for patients undergoing peritoneal dialysis. Ren Replace Ther 6: 8, 2020.","DOI":"10.1186\/s41100-019-0254-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hamada C, Honda K, Kawanishi K, et al. Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs 18: 243-250, 2015.","DOI":"10.1007\/s10047-015-0822-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 16: 1304-1305, 2001.","DOI":"10.1093\/ndt\/16.6.1304"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 26: 203-206, 2006 (in eng).","DOI":"10.1177\/089686080602600215"},{"key":"9","unstructured":"9. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 9: 187-189, 1993."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential effect of sirolimus <i>vs<\/i> prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 17: 2278-2280, 2002.","DOI":"10.1093\/ndt\/17.12.2278"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Brown EA, Bargman J, van Biesen W, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis - position paper for ISPD: 2017 update. Perit Dial Int 37: 362-374, 2017.","DOI":"10.3747\/pdi.2017.00018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Garosi G, Di Paolo N, Sacchi G, Gaggiotti E. Sclerosing peritonitis: a nosological entity. Perit Dial Int 25: S110-S112, 2005.","DOI":"10.1177\/089686080502503S28"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yang X, Tong Y, Yan H, Ni Z, Qian J, Fang W. High intraperitoneal interleukin-6 levels predict peritonitis in peritoneal dialysis patients: a prospective cohort study. Am J Nephrol 47: 317-324, 2018.","DOI":"10.1159\/000489271"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. L\u00fcdemann WM, Heide D, Kihm L, et al. TNF signaling in peritoneal mesothelial cells: pivotal role of Cflip<sub>L<\/sub>. Perit Dial Int 37: 250-258, 2017.","DOI":"10.3747\/pdi.2016.00138"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Po\u0142ubinska A, Pawlaczyk K, Kuzlan-Pawlaczyk M, et al. Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats. Kidney Int 57: 1182-1189, 2000.","DOI":"10.1046\/j.1523-1755.2000.00946.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lopes Barreto D, Struijk DG, Krediet RT. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. Am J Kidney Dis 65: 748-753, 2015.","DOI":"10.1053\/j.ajkd.2014.10.022"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsuo H, Tamura M, Kabashima N, et al. Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-\u03baB in peritoneal mesothelial cells. Kidney Int 69: 736-746, 2006.","DOI":"10.1038\/sj.ki.5000131"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lambie M, Chess J, Donovan KL, et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 24: 2071-2080, 2013.","DOI":"10.1681\/ASN.2013030314"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Davies SJ. Peritoneal solute transport and inflammation. Am J Kidney Dis 64: 978-986, 2014.","DOI":"10.1053\/j.ajkd.2014.06.030"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sawai A, Ito Y, Mizuno M, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol Dial Transplant 26: 2322-2332, 2011.","DOI":"10.1093\/ndt\/gfq702"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oh KH, Jung JY, Yoon MO, et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 25: 1639-1646, 2010.","DOI":"10.1093\/ndt\/gfp670"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Liu B, Goodwin JE. The effect of glucocorticoids on angiogenesis in the treatment of solid tumors. J Cell Signal 1: 42-49, 2020.","DOI":"10.33696\/Signaling.1.011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. La Milia V, Longhi S, Sironi E, Pontoriero G. The peritoneal sieving of sodium: a simple and powerful test to rule out the onset of encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis. J Nephrol 31: 137-145, 2018.","DOI":"10.1007\/s40620-016-0371-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lim W, Park C, Shim MK, Lee YH, Lee YM, Lee Y. Glucocorticoids suppress hypoxia-induced COX-2 and hypoxia inducible factor-1\u03b1 expression through the induction of glucocorticoid-induced leucine zipper. Br J Pharmacol 171: 735-745, 2014.","DOI":"10.1111\/bph.12491"},{"key":"25","first-page":"97","volume":"3","author":"JM Bailey","year":"1991","unstructured":"25. Bailey JM. New mechanisms for effects of anti-inflammatory glucocorticoids. BioFactors (Oxford, England) 3: 97-102, 1991.","journal-title":"BioFactors","ISSN":"https:\/\/id.crossref.org\/issn\/0951-6433","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Habib SM, Abrahams AC, Korte MR, et al. CD4-positive T cells and M2 macrophages dominate the peritoneal infiltrate of patients with encapsulating peritoneal sclerosis. PLoS One 10: e0120174, 2015.","DOI":"10.1371\/journal.pone.0120174"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1760-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T03:27:02Z","timestamp":1699068422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/21\/62_1760-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1760-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"article-number":"1760-23"}}